What versions of Sotolaxib are available?

Sotorasib is a targeted drug that specifically targets the KRAS G12C mutation. It is mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) who carry this mutation. KRAS G12C mutations are relatively common in non-small cell lung cancer. However, due to the complexity of the KRAS protein structure, effective targeted therapies have been lacking for a long time. The advent of sotorasibu breaks this limitation. It specifically binds to the KRAS G12C mutated protein and inhibits its activity, thereby preventing the proliferation of cancer cells. Clinical trials have confirmed that sotoraxib significantly prolonged the progression-free survival of patients and demonstrated a good response rate in relapsed and previously treated patients. It is a major advance in KRAS mutation-targeted therapy.

Currently, the drug versions of sotorasibu are mainly divided into two categories: original drugs and generic drugs.

1. Original drug: The original drug sotorasibu was developed by the American company Amgen (Amgen) and has been approved for marketing in the United States, the European Union and other regions. It is used to treat patients with advanced lung cancer that cannot be controlled by other therapies. The original drug is not yet on the market in China, so domestic patients are temporarily unable to purchase it through formal channels. At present, foreign versions of original drugs include European versions and Hong Kong versions, which are relatively expensive, with each box often selling for tens of thousands of yuan.

2. Generic drugs: In order to meet the medication needs of more patients, pharmaceutical companies in some countries and regions have launched generic drugs of sotorasibu. These generic drugs have the same active ingredients as the original drugs, but are more affordable and suitable for patients who require long-term treatment. The more common versions of generic drugs currently include those from Laos and India. Generic drugs produced by Lucius and Daxiong Pharmaceuticals in Laos are relatively affordable, with a box costing between more than one thousand yuan to more than two thousand yuan. The ingredients of these generic drugs are consistent with the original drugs, providing patients with more economical medication options.

In the future, as sotorasibu is promoted in the global market, more versions of generic drugs may become available, further expanding the accessibility of treatment. Once the drug is launched in China and is supported by medical insurance, it will provide patients with a more convenient and less burdensome treatment path.